Thalidomide Maintenance Treatment in DLBCL

Last updated: July 26, 2017
Sponsor: Nanfang Hospital of Southern Medical University
Overall Status: Active - Recruiting

Phase

3

Condition

Lymphoma

Treatment

N/A

Clinical Study ID

NCT03016000
NFL2016-B2
  • Ages 18-60
  • All Genders

Study Summary

This is a randomized, multi-center,phase III study to evaluate the ability of thalidomide maintenance therapy to prolong relapse-free survival in diffuse large B cell lymphoma(DLBCL).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • NCCN-IPI>1,

  • Known IPI, cell of origin and DHL at time of diagnosis,

  • Negative pregnancy test,

  • Men must agree not to father a child during the therapy,

  • 6 to 8 cycles R-CHOP/like, total of 8 x Rituximab,

  • CR, CRu

Exclusion

Exclusion Criteria:

  • Transformed lymphoma,

  • Secondary malignancy,

  • HIV positive,

  • Evidence of CNS involvement,

  • Cardiac dysfunction (systolic ejection fraction <50%),

  • Creatinine > 2.0 mg/dl

Study Design

Total Participants: 226
Study Start date:
July 26, 2017
Estimated Completion Date:
December 31, 2023

Study Description

This is a randomized, phase III study to evaluate the ability of thalidomide maintenance therapy to prolong relapse-free survival(RFS), in diffuse large B cell lymphoma(DLBCL).Patients will be enrolled after successful standard induction therapy (CR or CRu following standard R-CHOP-like therapy with 8 infusions of rituximab plus CHOP-like chemotherapy (4-8 cycles). Patients will be followed until an event occurs as defined in the protocol. To evaluate the clinical efficacy of thalidomide maintenance therapy as compared to observation in patients with DLBCL who have achieved a complete remission after appropriate first-line therapy, measured by RFS, 226 patients with DLCBL will be recruited.

Connect with a study center

  • Ru Feng

    Guangzhou, Guangdong 510515
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.